Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b infant study of recombinant meningococcal B vaccine with or without routine infant vaccinations
2008-001592-30Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease, meningococcal meningitis and meningococcemia (3 arms), sponsored by Novartis. Primary endpoints: Immunogenicity of routine infant vaccines during concomitant administration, Safety and tolerability and 1 more. Started May 2008; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal diseasemeningococcal meningitismeningococcemia
Beyond the preview
Go deeper on 2008-001592-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001592-30.